Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
3840 | 1824 | 45.6 | 93% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | B7 H4 | Author keyword | 154 | 91% | 3% | 63 |
2 | PD 1 | Author keyword | 131 | 46% | 12% | 210 |
3 | PD L1 | Author keyword | 121 | 55% | 8% | 151 |
4 | B7 H3 | Author keyword | 106 | 85% | 3% | 56 |
5 | B7 H1 | Author keyword | 96 | 65% | 5% | 92 |
6 | PROGRAMMED DEATH 1 | Author keyword | 56 | 59% | 3% | 63 |
7 | PROGRAMMED CELL DEATH 1 | Author keyword | 47 | 79% | 2% | 30 |
8 | PD L2 | Author keyword | 33 | 66% | 2% | 31 |
9 | PDCD1 | Author keyword | 29 | 77% | 1% | 20 |
10 | PROGRAMMED DEATH LIGAND 1 | Author keyword | 23 | 60% | 1% | 25 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | B7 H4 | 154 | 91% | 3% | 63 | Search B7+H4 | Search B7+H4 |
2 | PD 1 | 131 | 46% | 12% | 210 | Search PD+1 | Search PD+1 |
3 | PD L1 | 121 | 55% | 8% | 151 | Search PD+L1 | Search PD+L1 |
4 | B7 H3 | 106 | 85% | 3% | 56 | Search B7+H3 | Search B7+H3 |
5 | B7 H1 | 96 | 65% | 5% | 92 | Search B7+H1 | Search B7+H1 |
6 | PROGRAMMED DEATH 1 | 56 | 59% | 3% | 63 | Search PROGRAMMED+DEATH+1 | Search PROGRAMMED+DEATH+1 |
7 | PROGRAMMED CELL DEATH 1 | 47 | 79% | 2% | 30 | Search PROGRAMMED+CELL+DEATH+1 | Search PROGRAMMED+CELL+DEATH+1 |
8 | PD L2 | 33 | 66% | 2% | 31 | Search PD+L2 | Search PD+L2 |
9 | PDCD1 | 29 | 77% | 1% | 20 | Search PDCD1 | Search PDCD1 |
10 | PROGRAMMED DEATH LIGAND 1 | 23 | 60% | 1% | 25 | Search PROGRAMMED+DEATH+LIGAND+1 | Search PROGRAMMED+DEATH+LIGAND+1 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | B7 FAMILY | 344 | 64% | 18% | 333 |
2 | B7 H1 | 272 | 75% | 11% | 196 |
3 | PD 1 | 183 | 51% | 14% | 257 |
4 | PROGRAMMED DEATH 1 | 181 | 61% | 10% | 191 |
5 | B7 H1 EXPRESSION | 164 | 93% | 3% | 63 |
6 | B7 FAMILY MEMBER | 121 | 71% | 5% | 98 |
7 | PROGRAMMED DEATH 1 LIGAND 1 | 110 | 93% | 2% | 41 |
8 | PD L1 | 65 | 72% | 3% | 51 |
9 | CD223 | 56 | 89% | 1% | 25 |
10 | COSTIMULATORY MOLECULE B7 H3 | 53 | 95% | 1% | 18 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
PD-1 and its ligands in tolerance and immunity | 2008 | 859 | 149 | 80% |
The blockade of immune checkpoints in cancer immunotherapy | 2012 | 699 | 119 | 46% |
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? | 2015 | 19 | 177 | 45% |
The B7 family revisited | 2005 | 1127 | 149 | 44% |
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity | 2012 | 210 | 42 | 81% |
Clinical blockade of PD1 and LAG3-potential mechanisms of action | 2015 | 9 | 122 | 80% |
T cell exhaustion | 2011 | 461 | 107 | 24% |
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway | 2015 | 7 | 63 | 92% |
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection | 2007 | 421 | 89 | 70% |
Inhibitory B7-family molecules in the tumour microenvironment | 2008 | 255 | 127 | 64% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | BIOL DISCOVERY CALIF | 6 | 58% | 0.4% | 7 |
2 | IMMUNE REGULAT INTERVENT | 4 | 67% | 0.2% | 4 |
3 | BIOCHEM PHYSIOL BIOPHYS | 4 | 75% | 0.2% | 3 |
4 | CLIN IMMUNOL JIANGSU PROVINCE | 4 | 75% | 0.2% | 3 |
5 | JIANGSU CLIN IMMUNOL | 3 | 29% | 0.4% | 8 |
6 | YALE COMPREHENS CANC | 3 | 16% | 0.8% | 15 |
7 | DERMATOL ONCOL | 3 | 16% | 0.8% | 15 |
8 | CLIN IMMUNOL JIANGSU PROV | 2 | 23% | 0.5% | 9 |
9 | TUMOR BIOL TREATMENT | 2 | 18% | 0.6% | 11 |
10 | IMMUNOL GENOM MED | 2 | 15% | 0.7% | 13 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000228310 | ICOS//B7RP 1//ICOSL |
2 | 0.0000199123 | CTLA 4//IPILIMUMAB//CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 |
3 | 0.0000132326 | TIM 3//GALECTIN 9//TIM 1 |
4 | 0.0000097397 | FOXP3//TUMOR INFILTRATING LYMPHOCYTES//INTEGRAT CANC IMMUNOL |
5 | 0.0000081026 | RECOMBINANT VACCINE GRP//ABSCOPAL EFFECT//IMMUNOGENIC TUMOR CELL DEATH |
6 | 0.0000065790 | 4 1BB//OX40//CD137 |
7 | 0.0000061604 | BELAGENPUMATUCEL L//SRL172//PA MSHA |
8 | 0.0000060768 | CCDC134//TUMOR IMMUN TOLERANCE SECT//ANTIGEN SPECIFIC CTL FUNCTION |
9 | 0.0000056963 | CD28//CD80//B7 |
10 | 0.0000055158 | MYELOID DERIVED SUPPRESSOR CELLS//MDSC//MYELOID DERIVED SUPPRESSOR CELL |